Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Donor lymphocyte infusion therapy.

Karen S Roush1, Christopher D Hillyer

  • 1Department of Pathology and Laboratory Medicine, Transfusion Medicine Program, Emory University School of Medicine, 1362 Clifton Road NE, Atlanta, GA 30322, USA.

Transfusion Medicine Reviews
|April 10, 2002
PubMed
Summary

Donor lymphocyte infusion (DLI) shows promise in certain leukemias but carries risks like graft-versus-host disease. Research explores DLI

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitofusin agonists enhances long-term engraftment and potency of HSC cultures <i>in vivo</i>.

bioRxiv : the preprint server for biology·2025
Same author

Lysine succinylation precisely controls normal erythropoiesis.

Haematologica·2024
Same author

Phenotypic and proteomic characterization of the human erythroid progenitor continuum reveal dynamic changes in cell cycle and in metabolic pathways.

American journal of hematology·2023
Same author

Insights into highly engraftable hematopoietic cells from 27-year cryopreserved umbilical cord blood.

Cell reports. Medicine·2023
Same author

Discovery of Highly Potent Small Molecule Pan-Coronavirus Fusion Inhibitors.

Viruses·2023
Same author

Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays.

Viruses·2022

Area of Science:

  • Immunotherapy
  • Hematology
  • Oncology

Background:

  • Donor lymphocyte infusion (DLI) is an emerging therapy post-stem cell transplant.
  • It's explored for various cancers and viral infections.
  • Its effectiveness varies significantly across different diseases.

Purpose of the Study:

  • To review DLI's utility in diverse disease states.
  • To analyze the risks associated with DLI, particularly graft-versus-host disease.
  • To discuss strategies for mitigating risks while maintaining therapeutic benefits.

Main Methods:

  • Literature review of key studies on DLI efficacy and safety.
  • Analysis of DLI's application in hematopoietic and solid tumors.
  • Examination of DLI's role in viral modulation and disease prevention.

Main Results:

  • DLI demonstrates highest efficacy in chronic myelogenous leukemia.
  • Evidence of clear benefit is less robust in other studied diseases.
  • Graft-versus-host disease remains a significant risk, potentially outweighing benefits.

Conclusions:

  • DLI is a valuable tool in specific contexts, notably CML.
  • Careful patient selection and risk management are crucial for DLI therapy.
  • Further research and improved assessment tools are needed to optimize DLI's survival benefits.

Related Experiment Videos